Met-enkephalin: the brain's own natural painkiller
A tiny five-amino-acid molecule the body makes in the brain, spinal cord, gut, and adrenal glands that works like a built-in version of morphine; a natural body chemical, not a drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Endogenous peptide — produced naturally and routinely synthesized for research
Fork this card to add platform evidence →
Endogenous peptide — receptor binding and activity established in published literature
Fork this card to add platform evidence →
What this is
Met-enkephalin is a tiny five-amino-acid peptide (Tyr-Gly-Gly-Phe-Met) made naturally in the brain, spinal cord, gut, and adrenal glands. It was one of the first "endogenous opioids" ever discovered — the body's own morphine-like molecule, isolated from pig brain in 1975 by John Hughes and Hans Kosterlitz in Aberdeen (Hughes et al., Nature 1975). The same paper described its sibling Leu-enkephalin, which differs only at the final amino acid. Together they showed that the brain makes its own opioids; opioid drugs work because they happen to fit receptors that evolved for these peptides.
Met-enkephalin is one of several products cleaved from a larger precursor protein called proenkephalin A (the PENK gene). Each PENK molecule yields four copies of Met-enkephalin plus one copy of Leu-enkephalin and a handful of related extended peptides (Noda et al., Nature 1982).
History
The opioid receptor was identified in 1973, which immediately raised an obvious question: why does the mammalian brain have receptors for a poppy alkaloid? Hughes and Kosterlitz set out to find the natural ligand by extracting pig brains and testing the fractions on opioid-sensitive tissue preparations — the mouse vas deferens and guinea-pig ileum, where opioids reliably suppress electrically evoked contractions. The active fractions resolved to two pentapeptides with the sequences Tyr-Gly-Gly-Phe-Met and Tyr-Gly-Gly-Phe-Leu (Hughes et al., Nature 1975). They named them "enkephalins" — Greek for "in the head."
Seven years later, Noda and colleagues at Kyoto University cloned the bovine adrenal preproenkephalin cDNA, revealing that a single precursor protein carries four Met-enkephalin copies, one Leu-enkephalin, and the extended forms Met-enkephalin-Arg-Phe (heptapeptide) and Met-enkephalin-Arg-Gly-Leu (octapeptide), each flanked by paired basic residues that mark the cleavage sites (Noda et al., Nature 1982). This established the genetic architecture of the endogenous opioid system: three separate precursor genes (PENK for the enkephalins, POMC for β-endorphin, and PDYN for the dynorphins), each processed into a family of peptide products with distinct receptor preferences (Fricker et al., Mol Pharmacol 2020).
What it does
Met-enkephalin is one of the brain's natural painkillers and stress-modulators. It is released by inhibitory interneurons in the spinal cord dorsal horn and at brainstem sites like the periaqueductal gray, where it dampens transmission of pain signals heading to higher brain regions (García-Domínguez, Biomolecules 2024; Cullen & Cascella, StatPearls 2023). Outside the nervous system it is also produced in the adrenal medulla and by immune cells, where it acts on opioid receptors expressed on lymphocytes, monocytes, and dendritic cells.
Beyond pain modulation, Met-enkephalin functions as a tonic brake on cell proliferation through a non-classical opioid receptor called the opioid growth factor receptor (OGFr). This is the basis for the name "opioid growth factor" (OGF) used in the cancer literature (Zagon & McLaughlin, World J Gastroenterol 2014).
Mechanism
Met-enkephalin binds the δ-opioid receptor (DOR / OPRD1) and the μ-opioid receptor (MOR / OPRM1), with higher affinity at δ but meaningful activity at μ as well; affinity at the κ-opioid receptor is low (García-Domínguez, Biomolecules 2024; Cullen & Cascella, StatPearls 2023). Receptor engagement triggers Gi/o coupling, inhibiting adenylyl cyclase, closing voltage-gated calcium channels at presynaptic terminals, and opening inwardly-rectifying potassium channels postsynaptically. The net effect is reduced release of pain-related neurotransmitters (glutamate, substance P, CGRP) at nociceptive terminals and reduced postsynaptic excitability (García-Domínguez, Biomolecules 2024).
A second, distinct mechanism operates through the opioid growth factor receptor (OGFr), a nuclear-associated receptor unrelated to the classical seven-transmembrane opioid receptors. Through OGFr, Met-enkephalin delays the G1/S transition of the cell cycle, providing a tonic inhibitory tone on proliferation in both normal and neoplastic tissue. This is why intermittent blockade with low-dose naltrexone — which transiently removes opioid tone and triggers compensatory upregulation of OGF and OGFr — has been investigated as an anti-proliferative and immunomodulatory strategy (Zagon & McLaughlin, World J Gastroenterol 2014; Ludwig et al., Exp Biol Med 2017).
Pharmacokinetically, native Met-enkephalin has an extremely short half-life — on the order of minutes or less in circulation — because it is rapidly cleaved by neutral endopeptidase (neprilysin, historically called "enkephalinase"), aminopeptidase N, and other peptidases that attack the Tyr-Gly bond and the C-terminal residues. This short systemic half-life is the main reason therapeutic development has focused on stabilized analogs (including D-amino-acid substitutions and enantiomers), enkephalinase inhibitors, or local rather than systemic delivery (Turčić et al., Acta Pharm 2025; Ding et al., Amino Acids 2020).
Evidence
- Human: A Phase II open-label trial in 24 patients with advanced pancreatic cancer who had failed standard chemotherapy reported a clinical-benefit response in 53% of patients treated with weekly intravenous OGF (Met-enkephalin) at 250 µg/kg, with median survival approximately three times that of untreated historical comparators in the same setting and no adverse effects on hematologic or chemistry parameters (Smith et al., Open Access J Clin Trials 2010). A separate pilot study found serum [Met⁵]-enkephalin reduced in patients with multiple sclerosis and partially restored by low-dose naltrexone, supporting the OGF–OGFr axis as a candidate biomarker and target (Ludwig et al., Exp Biol Med 2017).
- Animal: In acetaminophen-induced liver injury in mice, both the natural L-enantiomer and a synthetic D-enantiomer of Met-enkephalin produced dose-dependent hepatoprotection across 0.5–20 mg/kg, with maximal protection at 5 mg/kg for the D-form and 7.5 mg/kg for the L-form; the protective effect was abolished by the opioid antagonist naltrexone, confirming opioid-receptor dependence (Turčić et al., Acta Pharm 2025).
- In vitro: Met-enkephalin activates δ- and μ-opioid receptors in heterologous expression systems with fast on-rates comparable to other peptide agonists like DAMGO (Huang et al., J Neurosci Res 2022). The enkephalin sequence (YGGFM motif) is deeply conserved across vertebrates; the same paper characterized opioid precursors in the Pacific hagfish, where multiple YGGFM motifs sit within canonical dibasic cleavage sites in a PENK-like precursor (Huang et al., J Neurosci Res 2022).
Known effects
- Endogenous analgesia — Mechanistic and electrophysiological, supported by the descending pain modulation literature (García-Domínguez, Biomolecules 2024).
- Immune modulation — Preclinical and ex vivo; enhances NK activity, dendritic-cell maturation, and CD8⁺ T-cell function (reviewed in Cullen & Cascella, StatPearls 2023).
- Anti-proliferative / OGF activity — Preclinical across multiple tumor types; one published Phase II human trial in pancreatic cancer (Smith et al., 2010).
- Hepatoprotection (L- and D-Met-enkephalin) — Preclinical, opioid-receptor-dependent (Turčić et al., 2025).
Safety signals
In the Phase II pancreatic cancer trial, weekly intravenous OGF at 250 µg/kg produced no adverse effects on hematologic or chemistry parameters, and quality-of-life measures suggested improvement rather than decrement (Smith et al., 2010). The published clinical experience with Met-enkephalin as OGF is small but consistently describes a benign acute toxicity profile in oncology contexts. Long-term safety, immunogenicity at chronic administration, and effects in non-oncology populations have not been systematically characterized in published trials.
Regulatory status
- US (FDA): Not approved. Investigational only.
- EU (EMA): Not approved.
- WADA: Endogenous opioid peptides as a class are not separately listed on the current Prohibited List; in-competition narcotics restrictions (S7) cover morphine and selected synthetic opioids, not native enkephalins.
Related peptides
- Leu-enkephalin — sibling pentapeptide YGGFL, co-discovered in the same 1975 Hughes/Kosterlitz isolation; differs only at the C-terminal residue and is slightly more δ-selective (Hughes et al., Nature 1975).
- β-endorphin — longer 31-residue endogenous opioid derived from a different precursor (POMC), primarily μ-selective (Fricker et al., Mol Pharmacol 2020).
- Dynorphin A — endogenous opioid from a third precursor gene (PDYN), preferentially κ-selective (Fricker et al., Mol Pharmacol 2020).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could the same gene produce different amounts of painkiller depending on which organ processes it?
If true, doctors might one day adjust pain relief by targeting the cutting enzymes rather than giving drugs. This could help people who need steady, adjustable pain control without the risks of external opioid medications.
Could the difference between two natural painkillers help the body sense injured or inflamed tissue?
If true, we might learn why the body keeps two almost identical painkillers, and how to design drugs that work better when tissues are damaged or swollen. People with inflammatory pain conditions like arthritis could benefit from smarter pain medications.
Could changing one building block of this brain chemical yield a painkiller with lower dependence risk?
If true, it could guide the design of pain relief options with reduced addiction risk. People with chronic pain, cancer pain, or post-surgical recovery might gain safer treatment choices.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9808787703514099 | boltz-2 |
| ranking score | 0.8505340814590454 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.503 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep04455,
sequence = {YGGFM},
target = {oprd1},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}